Effects of trimetazidine in combination with bisoprolol in patients with chronic heart failure and concomitant chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis

• Published in: Medicine (Baltimore) Vol. 100; no. 15; p. e25491
• Main Authors: Zhang, Xiaoyan, Ma, Shujuan, Fu, Baocai
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 16.04.2021
• Subjects: Adrenergic beta-1 Receptor Antagonists - administration & dosage; Bisoprolol - administration & dosage; Chronic Disease; Drug Therapy, Combination; Heart Failure - complications; Heart Failure - drug therapy; Humans; Meta-Analysis as Topic; Observational Studies as Topic; Pulmonary Disease, Chronic Obstructive - complications; Pulmonary Disease, Chronic Obstructive - drug therapy; Randomized Controlled Trials as Topic; Research Design; Study Protocol Systematic Review; Systematic Reviews as Topic; Treatment Outcome; Trimetazidine - administration & dosage; Vasodilator Agents - administration & dosage
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000025491

To the best of our knowledge, there is no study that has conducted a review investigating the clinical efficacy and safety of bisoprolol combined with trimetazidine on chronic heart failure (CHF) patients with chronic obstructive pulmonary disease (COPD). Therefore, in order to provide new evidence-based medical evidence for clinical treatment, we undertook a systematic review and meta-analysis to assess the effectiveness and safety of bisoprolol combined with trimetazidine on CHF patients with COPD. Seven electronic databases including Web of Science, Embase, PubMed, Wanfang Data, Scopus, Science Direct, Cochrane Library will be searched in April 2021 by 2 independent reviewers. For search on PubMed, the following search terms will be used: "trimetazidine, bisoprolol, chronic heart failure, chronic obstructive pulmonary disease." In order to achieve a consistency of extracted items, the data extractors will extract data from a sample of eligible studies. The outcomes include all-cause mortality and hospitalization for cardiac or/and respiratory causes; left ventricular structure and function; and functional scores. Review Manager software (v 5.4; Cochrane Collaboration) will be used for the meta-analysis. Two independent reviewers will assess the risk of bias of the included studies at study level. Any disagreements will be discussed and resolved in discussion with a third reviewer. The results of our review will be reported strictly following the PRISMA criteria. The review will add to the existing literature by showing compelling evidence and improved guidance in clinic settings. 10.17605/OSF.IO/ZWPRB.